Calcium Folinate Treatment of Spastic Paraplegia 56

NCT06478238 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai 6th People's Hospital

Phase

Early Phase 1

Started

2024-07-01

Last updated

2024-06-27

Condition(s) studied

Hereditary Spastic Paraplegia

Investigational drug(s) / intervention(s)

calcium folinate →

calcium folinate: Intravenous infusion and/or oral therapy

Study summary

SPG56 is one of the complicated and early-onset HSP subtypes caused by genetic mutations in CYP2U1. So far, there is no standardized and specific clinical therapy for SPG56. The goal of this clinical trial is to explore the efficacy and safety of calcium folinate in the treatment of SPG56 patients.

This study is prospective, open-label and single arm and this trial will last for 6 years. A total of 10 patients will participate and they will receive calcium folinate treatment and professional clinical evaluation regularly.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Patients meet the clinical diagnostic standard of hereditary spastic paraplegia (HSP); 2. Spastic paraplegia type 56 (SPG56) was diagnosed by CYP2U1 pathogenic mutation; 3. Patients are willing to participate in clinical trials and able to understand and comply with the research program. Exclusion Criteria: 1. Patients are allergic to the drugs involved in the study; 2. Other neurological diseases likely affecting the evaluation of study treatment; 3. Other medical conditions such as: heart disease, tumor, blood disease, liver disease, kidney disease, etc. in the past 1 year; 4. Pregnancy or lactating women or subjects who are unable to use appropriate contraception during the trial; 5. Participating in another study drug trial and used the investigational drug in the past 30 days; 6. Subjects have poor compliance or other factors that are not suitable for participating in the clinical trial.

Primary outcome measure(s)

GMFM-88 — At the end of the 5-year follow-up period
The change in the Gross Motor Function Measure-88 (GMFM-88) score from baseline (range: 0-264, higher scores mean a better outcome).

Trial sites (1)

Facility	City	Region	Status
Shanghai 6th People's Hospita	Shanghai	Shanghai Municipality	Recruiting

More Shanghai 6th People's Hospital trials in China

Clinical Evaluation of Salivary 1,5-Anhydroglucitol in Diabetes Starting soon

Public Perceptions Toward Robotic Surgery, Telesurgery and Telemedicine Recruiting

A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP Recruiting

MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma Recruiting

Validation of Five Seasons Sleep Tracking Mat for the Diagnosis of Obstructive Sleep Apnea Recruiting

Other trials for the same condition

A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP Recruiting

Rare Disease Registry Database for Movement Disorders in Southern Anhui Province Recruiting

A Prospective Cohort Study of ITB Treatment for HSP Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06478238 on ClinicalTrials.gov ↗ ← All trials in China